ReCerise and NCCS Forge Strategic Research Collaboration to Advance Hepatocellular Carcinoma Treatment ReCerise Therapeutics Inc. (“ReCerise”), a pioneering biotechnology company dedicated to the research and development of first-in-class oncology therapeutics,…
Sensorion Gets Positive Board Recommendation for SENS-501 Trial Sensorion a pioneering clinical-stage biotechnology company specializing in the development of innovative therapies for hearing loss disorders, has announced a significant milestone…
New International Guidelines Released for the Treatment of Candida Fungal Infections A groundbreaking global guideline for the diagnosis and treatment of Candida infections has been published in The Lancet Infectious…
Eikon Therapeutics Showcases Oblique Line Scan Tech in Nature Method Eikon Therapeutics, Inc., a clinical-stage biotechnology company that integrates advanced engineering with cutting-edge molecular and cell biology to accelerate drug…
Lantern Pharma Publishes PCT Patent for AI Model Predicting BBB Permeability Lantern Pharma Inc. (NASDAQ: LTRN), a leading artificial intelligence (AI) company dedicated to advancing cancer therapies and transforming the…
Ventus Therapeutics Names Dr. Mona Kotecha as Chief Medical Officer Ventus Therapeutics, a clinical-stage biopharmaceutical company, has announced the appointment of Mona Kotecha, M.D., as its new Chief Medical Officer…
Alzamend Neuro Advances Alzheimer’s and Psychiatric Disorder Research with Tesla-Developed Head Coil for Phase II Trials Alzamend Neuro, Inc. (Nasdaq: ALZN) (“Alzamend”), a clinical-stage biopharmaceutical company dedicated to developing innovative…
Celerion Expands UK Phase 1 Trials at Queen’s University Belfast’s iREACH Health Celerion, a global leader in early clinical research, has announced a strategic agreement to relocate its U.K. Phase…
Stablepharma Secures Prestigious €2.5 Million EIC Accelerator Grant, Recognised Among Europe’s Leading Innovators UK-based biotechnology company Stablepharma Ltd has secured €2.5 million in funding from the highly competitive European Innovation…
Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical-stage gene editing company leveraging its proprietary ARCUS® platform to develop in vivo gene editing therapies for diseases with high unmet needs, has announced…
Reverb Therapeutics Raises $12M to Advance Amplify•R™ Platform Reverb Therapeutics, a biotechnology company pioneering innovative approaches to harness the natural immune system and cytokine signaling for the treatment of life-threatening…
PharmaJet to Showcase Advantages of Needle-Free Intradermal Delivery at Medical Conference in Ethiopia PharmaJet®, a company dedicated to enhancing the performance and outcomes of injectables through its innovative technology, has…